Results of the largest clinical trial in type 2 diabetes patients demonstrating positive effects of fenofibrate therapy on cardiovascular events Part 2
Patients be by ways all for a median of five years and evaluate for the effect of micronised fenofibrate once respectively sunshine versus placebo on coronary heart and cardiovascular virus in patients implicit hue 2 diabetes. Participants were evaluated both six months for end dealings and sanctuary examination.
The FIELD revise be creative in that the tolerant population include the largest subgroup of opening blocking patients ever incorporated in a type 2 diabetes tribulation; 7664 patients (78% of the study population) festival no signs of prior cardiovascular disease at study foyer. The median duration of diabetes was 5 years and the patients’ blood glucose level were resourcefully controlled (median HbA1c = 6.9%). Three-fifths (60%) of patients were on diet counsel or monotherapy alone for their diabetes. Moreover, few patients at baseline suffer from retinopathy (8%) or nephropathy (3%). About one-third (38%) of patients hold both triglyceride concentration of > 1.7 mmol/l and HDL-cholesterol levels of < 1.03 mmol/l in man and < 1.29 mmol/l in women. The majority (60%) of patients were underneath 65 years of age at screening.
The geographical field and similar period of hazard be: – Hautes-Pyrénées ( Tarbes municipal and surroundings), from the 25th October 2007 onwards – Gers (Auch city and surroundings), from the 1st November onwards – Seine-et-Marne, from the 15th December onwards – Calvados (Lisieux city and Thury Harcourt small town and their surroundings), from the 15th December onwards The risk to human from this time be considered dwindling, nonetheless the HPA is advise everyone who have continuous a dog bite while itinerant or pass the time inwardly the parish of France during the date detailed above to aim cue medical warning from their GP or NHS Direct.
Treatment effects were evocatively larger in the patients devoid of past cardiovascular disease than in those with previous cardiovascular disease (comprising 78% of all trial participants). In this subgroup of patients, investigators buzz: – A significant 19-percent reduction in total cardiovascular disease events (p<0.004, secondary endpoint), similar to an entire venture reduction rate of 2 percent, or the indistinguishable of need to treat 50 patients for 5 years to ban one or more CVD events in one patient; – A significant 25-percent reduction in coronary events (p=0.014, primary endpoint) in a post-hoc subgroup analysis.
genetal herpes for herpes treatment on buyzoviraxonline.com store!
The URI to TrackBack this entry is: http://medicinelibrary.edublogs.org/2008/11/27/results-of-the-largest-clinical-trial-in-type-2-diabetes-patients-demonstrating-positive-effects-of-fenofibrate-therapy-on-cardiovascular-events-part-2/trackback/
Leave a Comment
You must be logged in to post a comment.